0001193125-19-007056.txt : 20190111 0001193125-19-007056.hdr.sgml : 20190111 20190111131736 ACCESSION NUMBER: 0001193125-19-007056 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190111 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190111 DATE AS OF CHANGE: 20190111 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shire plc CENTRAL INDEX KEY: 0000936402 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37896 FILM NUMBER: 19521995 BUSINESS ADDRESS: STREET 1: BLOCK 2, MIESIAN PLAZA STREET 2: 50-58 BAGGOT STREET LOWER CITY: DUBLIN 2 STATE: L2 ZIP: D02 HW68 BUSINESS PHONE: 353-1-609-6000 MAIL ADDRESS: STREET 1: BLOCK 2, MIESIAN PLAZA STREET 2: 50-58 BAGGOT STREET LOWER CITY: DUBLIN 2 STATE: L2 ZIP: D02 HW68 FORMER COMPANY: FORMER CONFORMED NAME: Shire Ltd. DATE OF NAME CHANGE: 20080523 FORMER COMPANY: FORMER CONFORMED NAME: Shire plc DATE OF NAME CHANGE: 20051125 FORMER COMPANY: FORMER CONFORMED NAME: SHIRE PHARMACEUTICALS GROUP PLC DATE OF NAME CHANGE: 19980302 8-K 1 d685331d8k.htm FORM 8-K FORM 8-K
Table of Contents

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 11, 2019

 

 

SHIRE PLC

(Exact name of registrant as specified in its charter)

 

 

 

Jersey, Channel Islands   0-29630   98-0601486
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

Block 2

Miesian Plaza

50-58 Baggot Street Lower

Dublin 2

Republic of Ireland

(Address of principal executive offices)

Registrant’s telephone number, including area code: +353 1 429 7700

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 


Table of Contents
Item 8.01

Other Events

Shire plc and Shire Acquisitions Investments Ireland DAC have issued the press release attached hereto as Exhibit 99.1, which is incorporated by reference herein.

 

Item 9.01

Financial Statements and Exhibits

 

(d)

Exhibits

 

Exhibit
No.

  

Description

99.1    Press Release dated January 11, 2019.


Table of Contents

EXHIBIT INDEX

 

Exhibit
No.

  

Description

  99.1    Press Release dated January 11, 2019.


Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    SHIRE PLC  
Date: January 11, 2019          By:  

/s/ Susan O’Reilly

      
      Name:   Susan O’Reilly  
      Title:   Company Secretary  
EX-99.1 2 d685331dex991.htm EXHIBIT 99.1 EXHIBIT 99.1

Exhibit 99.1

Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange

Dublin, Ireland – January 11, 2019 – Shire plc (“Shire”) and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire (“SAIIDAC”), announced today that they have notified the New York Stock Exchange (the “NYSE”) of their intention to apply for the voluntary delisting of SAIIDAC’s outstanding 1.900% Senior Notes due 2019, 2.400% Senior Notes due 2021, 2.875% Senior Notes due 2023 and 3.200% Senior Notes due 2026 (collectively, the “Notes”), which are guaranteed by Shire.

Background and reasons for the delisting

The Notes were originally issued on September 23, 2016. Pursuant to Rule 12h-5 under the United States Securities Exchange Act of 1934, as amended (the “Exchange Act”). However, SAIIDAC has been exempt from the periodic reporting requirements under the Exchange Act in connection with the Notes since Shire has been including in its financial statements a footnote providing the condensed consolidating financial information of SAIIDAC required to be included therein by Rule 3-10 of Regulation S-X.

On January 8, 2019, Takeda Pharmaceutical Company Limited (TSE: 4502, NYSE: TAK), a Japanese joint-stock corporation (“Takeda”), acquired all of the issued and to-be-issued share capital of Shire pursuant to a Scheme of Arrangement under Article 125 of the Companies (Jersey) Law 1991, as amended. As a result, Shire and SAIIDAC became wholly-owned subsidiaries of Takeda, and the listings of Shire’s common shares on the London Stock Exchange and of American Depositary Shares (“ADSs”) representing Shire’s common shares on the NASDAQ Global Market were terminated.

Shire intends to file with the United States Securities and Exchange Commission (the “Commission”), among other things, a notice on Form 15 to suspend the periodic reporting requirements under the Exchange Act applicable to it in connection with the terminated listing of its ADSs. Shire also intends to take the necessary steps to suspend the periodic reporting requirements under the Exchange Act applicable to it or its other subsidiaries in connection with any other class of securities, including the outstanding 1.875% Senior Notes due 2020, 3.600% Senior Notes due 2022, 4.000% Senior Notes due 2025 and 5.250% Senior Notes due 2045 issued by Baxalta and subsequently guaranteed by Shire (collectively, the “Baxalta Notes”).

Given these circumstances, Shire, SAIIDAC and Takeda have concluded that the costs of compliance, the demands on management’s time and the resources required to maintain the listing of the Notes on the NYSE and to satisfy the periodic reporting obligations applicable to the Notes under the Exchange Act are greater than the benefits received by the Shire, SAIIDAC and Takeda and the holders of the Notes, and have decided to terminate the listing of the Notes on the NYSE.


Delisting Schedule

Shire and SAIIDAC intend to file an application on Form 25 for the voluntary delisting of the Notes no fewer than 10 days following the publication of this notice and the delivery of the related notice to the NYSE of their intention to apply for delisting. It is currently expected that such filing will occur on or around January 21, 2019. Under the rules of the Commission, the delisting will become effective 10 days following the filing of the Form 25, or on or around January 31, 2019. On the date such delisting becomes effective, Shire and SAIIDAC also intend to file with the Commission a notice of suspension of periodic reporting obligations under the Exchange Act on Form 15, at which time the periodic reporting obligations in connection with the Notes will be suspended.

Future Plans and Proposed Alternative Listing

Following the completion of the delisting and deregistration/suspension process described above, neither of Shire nor SAIIDAC will file periodic reports with the Commission in connection with the Notes. As noted above, Shire also intends to take the necessary steps to suspend the periodic reporting requirements under the Exchange Act applicable to it or its other subsidiaries in connection with any other class of securities, and it is expected that such requirements will be suspended substantially simultaneously with those relating to the Notes.

Takeda will continue to file periodic reports with the Commission in connection with the listing of its ADSs on the NYSE.

SAIIDAC has not, and does not intend to, arrange for the listing and/or registration on another national securities exchange, as defined under the Exchange Act, or for quotation of its security in a quotation medium, as defined in Rule 15d2-11 under the Exchange Act. SAIIDAC intends to apply for the listing of the Notes on the Singapore Exchange Securities Trading Limited, with the listing expected to occur following the completion of the delisting and deregistration/suspension process described above.

Following the completion of the delisting and deregistration/suspension process described above, Takeda also intends to guarantee the respective obligations of SAIIDAC under the Notes and of Baxalta under the Baxalta Notes. However, as neither of the Notes nor the Baxalta Notes will be subject to periodic reporting obligations under the Exchange Act, Takeda does not plan to include in its financial statements a footnote containing the condensed consolidating financial information of SAIIDAC or Shire contemplated by Rule 3-10 of Regulation S-X.

For further information please contact:

 

Shire         

Christoph Brackmann (Investor Relations)

   christoph.brackmann@shire.com    +41 41 288 41 29   

Sun Kim (Investor Relations)

   sun.kim@shire.com    +1 617 588 8175   

Scott Burrows (Investor Relations)

   scott.burrows@shire.com    +41 41 288 4195   

Katie Joyce (Media)

   kjoyce@shire.com    +1 781 482 2779   
Takeda         

Elissa Johnsen (Media – outside of Japan)

   elissa.johnsen@takeda.com    +1 224 554 3185   

Kazumi Kobayashi (Media – within Japan)

   kazumi.kobayashi@takeda.com    +81 3 3278 2095   

Tsuyoshi Tada (Media – within Japan)

   tsuyoshi.tada@takeda.com    +81 3 3278 2417   

Takashi Okubo (Investor Relations)

   takeda.ir.contact@takeda.com    +81 3 3278 2306   


Forward-Looking Statements

This release contains statements about Shire, SAIIDAC and Takeda that are or may be forward looking statements, including all statements other than statements of historical facts. Such forward looking statements often, but not always, include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or words or terms of similar substance or the negative thereof. By their nature, forward-looking statements involve risk and uncertainty, because they relate to events and depend on circumstances that will occur in the future. The factors described in the context of such forward-looking statements herein could cause actual results and developments to differ materially from those expressed in or implied by such forward-looking statements. Although it is believed that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that such expectations will prove to have been correct and you are therefore cautioned not to place undue reliance on these forward-looking statements which speak only as at the date of this release.

Risk factors that may affect the future results of Takeda, Shire and their subsidiaries are contained in Takeda’s Registration Statement on Form 20-F, including the risks outlined under “Item 3. Key Information—D. Risk Factors”, and in Shire’s most recent Annual Report on Form 10-K and in Shire’s subsequent Quarterly Reports on Form 10-Q, in each case including those risks outlined in ‘ITEM1A: Risk Factors’, and in Shire’s subsequent reports on Form 8-K and other Securities and Exchange Commission filings (available at www.takeda.com, www.shire.com and www.sec.gov). The contents of such reports are not incorporated by reference into, nor do they form part of, this release. These risk factors expressly qualify all forward-looking statements contained in this release and should also be considered by the reader.

All forward-looking statements attributable to Takeda, Shire or SAIIDAC or any person acting on their behalf are expressly qualified in their entirety by this cautionary statement. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof. Except to the extent otherwise required by applicable law, neither Takeda nor Shire nor SAIIDAC undertake any obligation to update or revise forward-looking statements, whether as a result of new information, future events or otherwise.

NOTES TO EDITORS

Shire is now part of Takeda.

www.takeda.com

www.shire.com